Responses
Clinical/translational cancer immunotherapy
Original research
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Compose a Response to This Article
Other responses
No responses have been published for this article.